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Abstract 
Introduction 
The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term 
anticoagulation with vitamin K antagonists (VKA) such as warfarin.  Non-VKA oral anticoagulants (NOAC), 
which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the 
treatment of venous thromboembolism (VTE) in major phase III prospective randomised controlled trials 
(RCT), but the results may not be directly generalisable to patients with APS. 
Aims 
 
 
The primary aim is to demonstrate, in patients with APS and previous VTE, with or without systemic 
lupus erythematosus (SLE), that the intensity of anticoagulation achieved with rivaroxaban is not inferior 
to that of warfarin. Secondary aims are to compare rates of recurrent thrombosis, bleeding and the 
quality of life in patients on rivaroxaban with those on warfarin.  
Methods  
RAPS is a phase II/III prospective non-inferiority RCT in which eligible patients with APS, with or without 
SLE, who are on warfarin, target International Normalised Ratio (INR) 2.5 for previous VTE, will be 
randomised either to continue warfarin (standard of care) or to switch to rivaroxaban. Intensity of 
anticoagulation will be assessed using thrombin generation (TG) testing, with the endogenous thrombin 
potential (ETP) as the key parameter. The primary outcome is the percentage change in ETP from 
randomisation to day 42. Markers of in vivo coagulation activation, prothrombin fragment 1.2, thrombin 
antithrombin complex and D-dimer, will also be measured. 
Discussion 
If RAPS demonstrates that i) that the anticoagulant effect of rivaroxaban is not inferior to that of 
warfarin using TG testing and ii) the absence of any adverse effects that cause concern with regard to 
the use of rivaroxaban, this would provide sufficient supporting evidence to make rivaroxaban a 
standard of care for the treatment of APS patients with previous VTE, requiring a target INR of 2.5.  
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